Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.
about
Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disordersTissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's diseaseStimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2Mouse models of polyglutamine diseases: review and data table. Part IGenetics and neuropathology of Huntington's diseaseTranscriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasisHDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophyMaintenance of basal levels of autophagy in Huntington's disease mouse models displaying metabolic dysfunctionHuntingtin and its role in neuronal degenerationNormal huntingtin function: an alternative approach to Huntington's diseaseMetabolism in HD: still a relevant mechanism?Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulationGenetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesisHdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's diseaseImpaired brain creatine kinase activity in Huntington's disease.Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.A neuroprotective phase precedes striatal degeneration upon nucleolar stress.Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1.High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington's disease expansion mutation carriers shows normal mitochondrial respiratory function.Age-associated chromatin relaxation is enhanced in Huntington's disease mice.Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease.Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysisFull-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expressionHuntington disease models and human neuropathology: similarities and differencesCalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease.Body composition in premanifest Huntington's disease reveals lower bone density compared to controlsGenome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.Parvalbumin deficiency and GABAergic dysfunction in mice lacking PGC-1alphaIn vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects.The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease.Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice.Skeletal muscle pathology in Huntington's diseasePGC-1α provides a transcriptional framework for synchronous neurotransmitter release from parvalbumin-positive interneurons.Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1αAltered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's diseaseDominant effects of the Huntington's disease HTT CAG repeat length are captured in gene-expression data sets by a continuous analysis mathematical modeling strategySuberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's diseaseMitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
P2860
Q24562763-D52931A2-49C6-47FF-B7B5-59997EF10586Q24618141-A62B9390-B182-47D2-870C-070F46B8A4B3Q24681194-CD28E911-B8DD-4441-BAC5-FFD825BE328BQ26853025-877286E6-66D4-4A2B-95B6-3E90C307C77BQ27023050-66B1FEC1-4461-43A1-9947-E6C631E41902Q27026549-98D55F37-984E-47A2-BB33-319C54AB6C10Q27311425-56C24D32-2790-4726-81BD-AAE5762E5B1EQ27341821-65CC4CF0-82CA-481E-8029-6DF89A033526Q28281434-3AC39732-7016-446D-B185-779D8D95FCF2Q28281904-663794CC-4580-48AD-952D-6F8373F35BF9Q28394301-E2C10841-D87E-4F7B-B699-CEDB4D831A7FQ28479035-5DE065AD-B200-44A4-999B-6BB3EE34F35FQ28507529-A49BB1B4-E5F3-4849-A24B-B0B70D5580E6Q28743929-F898CDF6-D449-4C67-8433-BFCD19F5017EQ30468147-10921805-E1CB-4BAE-850A-CCDF47196359Q30480013-5B9F462E-6E8C-4565-8D87-37EC59A9AAD4Q30549660-E1E4E938-3767-40FB-96A9-93633E665954Q31002507-F096BE4B-8C0D-4221-9B44-392346C5BD58Q31129663-DD45535F-234C-40C7-A0EF-16065E8F2E5FQ33562672-39137BD2-D3EF-4F67-BE33-821D850DDDBDQ33563614-6F728597-8F8A-4124-A48A-D692A39B58CDQ33663335-AB74132A-E88C-44C1-87FC-A6A8728D71B4Q33755822-D0C25677-8525-49D1-B704-DCFE20F92E7CQ33755845-E3C5EC97-A709-4FE6-970A-A0948C095625Q33760994-7C2E2C0E-096E-437A-BA55-53BA70DA1877Q33773689-79FB40E7-8F09-4C48-89FB-B0B061EF9D46Q33838303-EA779D41-9DA6-46D0-B731-D2D5921918A7Q33911613-4B13860B-B9AE-4FF9-BDE0-6ECDC03FB46BQ33922914-91987C66-17C2-43AF-99C8-C5485DFEA965Q33980357-BCFD15B3-677B-40BA-BF99-7B622B71EA47Q34011801-341317D6-A6AF-407C-9F04-D1C63BAF8ECEQ34042260-5622990A-9DEC-45D3-8C69-E958F276E8DFQ34060224-22248E8B-8566-4588-AC37-D65569537F8BQ34292092-7A1E1905-100D-4A7A-B742-DFEBBFFD40B4Q34383492-2130B7D7-2527-4251-99CA-6934798B65EDQ34391101-130AF07B-1811-472A-80D5-BFD64C4CEE97Q34409630-BB298029-E49B-422B-B16D-069710E6DD16Q34675885-C3F5E855-F0C1-4366-B646-BFAD81E62599Q34763178-A013476B-6893-4DEB-A3E2-5ACCE4A51178Q34994779-C0A18331-819F-4599-B076-CCA840CE2013
P2860
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Dysregulation of gene expressi ...... l changes in muscle and brain.
@en
Dysregulation of gene expressi ...... l changes in muscle and brain.
@nl
type
label
Dysregulation of gene expressi ...... l changes in muscle and brain.
@en
Dysregulation of gene expressi ...... l changes in muscle and brain.
@nl
prefLabel
Dysregulation of gene expressi ...... l changes in muscle and brain.
@en
Dysregulation of gene expressi ...... l changes in muscle and brain.
@nl
P2093
P356
P1476
Dysregulation of gene expressi ...... l changes in muscle and brain.
@en
P2093
Andrew D Strand
Anne B Young
Annette M Woods
Dimitri Krainc
Donald A Bergstrom
Edmond Y Chan
James M Olson
Nikki L Peters
Sarah A Hanson
Stephen J Tapscott
P304
P356
10.1093/HMG/11.17.1911
P577
2002-08-01T00:00:00Z